DRUG — Bright Minds Biosciences Inc. | XLV Holdings | StockAdder

(DRUG)

Bright Minds Biosciences Inc.

Live chart and latest DRUG stock news.

Sector ETF → XLV Health Care Select

Chart powered byTradingView— professional charts for every trader.Try it free →

DRUG News

Jefferies initiates Bright Minds stock with buy on epilepsy drug

Apr 13, 2026 MarketBeat

Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group

Apr 13, 2026 Yahoo Finance

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

Mar 24, 2026 The Motley Fool

Why Bright Minds Biosciences Stock Topped the Market on Monday

Nov 17, 2025 GlobeNewswire

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Jan 7, 2026 Trefis

Bright Minds Biosciences Stock Pre-Market (+10%) : BMB-101 Phase 2 Topline Data Release

Jan 6, 2026 Stock Titan

Experimental drug sharply cuts hard-to-treat seizures, boosts REM

Jan 6, 2026 Yahoo Finance

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials

Feb 18, 2026 MarketBeat

Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Here's Why

Apr 7, 2026 Yahoo Finance

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

Oct 15, 2025 MarketBeat

Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.4% Higher - What's Next?

Apr 6, 2026 Investing.com

Bright Minds Biosciences stock price target raised to $147 by BTIG

Jan 7, 2026 MarketBeat

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from Brokerages

Mar 28, 2026 Investing.com

Bright Minds Biosciences launches $100 million public offering

Jan 6, 2026 MarketBeat

Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research